Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases (Q83226250)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

10

Daisuke Aoki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

8

Keiichi Fujiwara

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

9

Tanri Shiozawa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1

Masashi Takano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Yoshihiro Kikuchi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Kazuya Kudoh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Tomoko Goto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Kenichi Furuya

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Ryoko Kikuchi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Tsunekazu Kita

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

18 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Clinical Oncology

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

605-609

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10147-010-0177-z

20 January 2020

exact match

0 references

cites work

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

1 reference

12 December 2020

Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma

1 reference

12 December 2020

Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial

1 reference

12 December 2020

Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease

1 reference

12 December 2020

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

1 reference

12 December 2020

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

1 reference

12 December 2020

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

1 reference

12 December 2020

Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas

1 reference

12 December 2020

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

1 reference

12 December 2020

Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.

1 reference

12 December 2020

Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy.

1 reference

12 December 2020

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

1 reference

12 December 2020

Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma

1 reference

12 December 2020

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

12 December 2020

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

1 reference

12 December 2020

Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an ind

1 reference

12 December 2020

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

1 reference

12 December 2020

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary

1 reference

12 December 2020

Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy

1 reference

12 December 2020

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

12 December 2020

TOR, a central controller of cell growth

1 reference

12 December 2020

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary

1 reference

12 December 2020

Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.

1 reference

12 December 2020

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

1 reference

12 December 2020

10.1007/S10147-010-0177-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21243393%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference